CIDEB and metabolic dysfunction-associated steatotic liver disease: In conclusion, our findings show that targeting CIDEB may offer potential therapeutic strategies for MASLD, and our work suggests that a disease defining manifestation of Cideb mutation is increased β-oxidation.